KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Intangibles: 2009-2025

Historic Intangibles for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $233.1 million.

  • Biomarin Pharmaceutical's Intangibles fell 10.66% to $233.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $233.1 million, marking a year-over-year decrease of 10.66%. This contributed to the annual value of $255.3 million for FY2024, which is 13.38% down from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's Intangibles stood at $233.1 million, which was down 2.72% from $239.6 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's Intangibles' 5-year high stood at $405.9 million during Q1 2021, with a 5-year trough of $233.1 million in Q3 2025.
  • Its 3-year average for Intangibles is $274.1 million, with a median of $265.5 million in 2024.
  • Data for Biomarin Pharmaceutical's Intangibles shows a maximum YoY dropped of 15.98% (in 2023) over the last 5 years.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Intangibles stood at $388.7 million in 2021, then dropped by 12.89% to $338.6 million in 2022, then declined by 12.96% to $294.7 million in 2023, then fell by 13.38% to $255.3 million in 2024, then decreased by 10.66% to $233.1 million in 2025.
  • Its last three reported values are $233.1 million in Q3 2025, $239.6 million for Q2 2025, and $247.3 million during Q1 2025.